MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.25 +3.98%

+$0.05 today

Market cap
$129.06M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 0.97M

Average 0.95M

MXCT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

MaxCyte, Inc.NASDAQ: MXCT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 106.88M shares rose 0.9% year over year, in line with the +1.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.9% toward the trailing-twelve-month pace of +1.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
106.88M+0.4% QoQ
Last fiscal yearDec 2025
106.43M+1.5% YoY
LTMMar 2026
106.51M+1.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.9%——
1 year+1.5%——
3-year CAGR+1.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
106.43M USD
Year-over-year change
+1.5%
4-year CAGR
+4.1%

Weighted Avg Shares (Diluted) vs competitors

How MXCT compares with its peers on the latest reported figures

  • MXCT's LTM Mar 2026 weighted avg shares (diluted) of 106.51M shares is the 3rd highest of the 11 companies compared; the peer median is 40.05M shares.
  • Its year-over-year change of +1.3% is the 8th highest of 11, against a peer median of +14.8%.
  • Over three fiscal years its annual growth of +1.5% compares with a peer median of +9.5%.
MXCT Competitors Peer median
Weighted Avg Shares (Diluted) for MXCT and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +51.8%+22.0%
OWLTOwlet, Inc.LTM Mar 2026149.39M +1085.6%+313.6%
MXCTMaxCyte, Inc.LTM Mar 2026106.51M +1.3%+1.5%
NNOXNano-X Imaging Ltd.LTM Dec 202564.81M +10.5%+7.4%
CATXPerspective Therapeutics, Inc.LTM Mar 202654.95M -21.6%+10.4%
TLSITriSalus Life Sciences, Inc.LTM Mar 202643.78M +66.1%+8.6%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202636.32M -23.4%+1.9%
PROFProfound Medical Corp.LTM Mar 202631.8M +21.2%+13.2%
AVRAnteris Technologies Global Corp.LTM Mar 202623.58M -20.8%-13.1%
PREPrenetics Global LimitedLTM Mar 202615.04M +18.8%+40.5%
LNSRLENSAR, Inc.LTM Mar 202612.87M +10.8%+5.6%
Peer median (excluding MXCT) 40.05M+14.8%+9.5%

Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.89M44.26M41.29M38.63M33.03M
Cost of Revenue3.65M5.1M4.74M7.1M6.22M
Gross Profit30.25M39.16M36.55M31.53M26.8M
Gross Margin89.2%88.5%88.5%81.6%81.2%
Research & Development15.41M19.51M23.82M22.23M20.82M
Selling, General & Admin31.68M44.48M57.04M56.35M47.04M
Operating Expenses48.44M66.52M84.85M82.72M72.09M
Depreciation & Amortization1.42M2.7M4.17M4.79M5.14M
EBITDA(16.61M)(20.75M)(33.75M)(36.27M)(39.49M)
EBITDA Margin-49.0%-46.9%-81.7%-93.9%-119.6%
Operating Income(18.19M)(27.36M)(48.3M)(51.2M)(45.29M)
Operating Margin-53.7%-61.8%-117.0%-132.5%-137.1%
Interest Income150.8K3.92M10.38M10.14M7.27M
Interest Expense1.04M126.9K000
Other Income / Expenses(893.6K)3.79M10.38M10.14M655K
Income Before Tax(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Pre-Tax Margin-56.3%-53.3%-91.8%-106.3%-135.1%
Income Tax Expense00000
Net Income(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Net Margin-56.3%-53.3%-91.8%-106.3%-135.1%
EPS (Basic)(0.22)(0.19)(0.37)(0.39)(0.42)
EPS (Diluted)(0.22)(0.19)(0.37)(0.39)(0.42)
Weighted Avg Shares90.62M101.7M103.27M104.85M106.43M
Weighted Avg Shares (Diluted)90.62M101.7M103.27M104.85M106.43M

MaxCyte, Inc.

NASDAQ:MXCT

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.